Semaglutide wins a kidney label after the FLOW outcome trial
Ozempic is now approved to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
What's new
FDA approved a new indication for Ozempic (semaglutide) in type 2 diabetes with chronic kidney disease, based on the FLOW outcome trial.
Why it matters
This is a hard outcome, not a lab value. Kidney failure means dialysis or transplant, and few drugs have shown they delay it.
What's next
Nephrology guidelines are expected to place GLP-1 drugs alongside existing kidney-protecting medicines.
Semaglutide, the peptide in Ozempic, received an additional US approval to reduce the risk of kidney disease getting worse, kidney failure and death from cardiovascular causes in adults with type 2 diabetes and chronic kidney disease.
The trial
FLOW randomised about 3,500 people with type 2 diabetes and chronic kidney disease to weekly semaglutide or placebo, on top of standard care. An independent committee stopped it early because the benefit was already clear.
- The main combined outcome (kidney failure, a large lasting drop in kidney function, or death from kidney or heart causes) was 24% less likely on semaglutide.
- The decline in kidney filtering function was slower.
- Deaths from any cause were also lower.
Why outcome trials matter
Many drugs improve a number on a lab report. Far fewer change what happens to patients. FLOW measured events people actually experience, which is why regulators and guideline writers weigh it heavily.
How it fits with other treatments
People with diabetic kidney disease already take blood pressure medicines that protect the kidney and, increasingly, SGLT2 inhibitors. FLOW participants could be on those too, so the benefit appears to add to existing care rather than replace it.
Kidney doctors have waited a long time for more than one drug class that slows the slide toward dialysis.
